바이오의약품 시장 규모, 점유율, 동향 분석 보고서 : 분자별, 질환별, 약물 유형별, 개발 단계 유형별, 투여 경로별, 처방 유형별, 판매 채널별, 지역별, 부문별 예측(2026-2033년)

Biopharmaceutical Market Summary

The global biopharmaceutical market size was estimated at USD 484.38 million in 2025 and is projected to reach USD 816.30 million by 2033, growing at a CAGR of 6.55% from 2026 to 2033. The biopharmaceutical industry's growth is driven by increasing demand for targeted therapies, advancements in biotechnology, the rising prevalence of chronic diseases, and an aging population.

The biopharmaceutical industry is witnessing rapid growth, driven by significant advancements in biotechnology and drug development. Innovations in vaccine technology, monoclonal antibodies, gene therapies, and next-generation biologics are transforming treatment paradigms across multiple therapeutic areas. These breakthroughs enhance treatment efficacy, improve patient outcomes, and address unmet medical needs. Recent developments highlight the impact of these advancements on the global healthcare landscape, underscoring the pivotal role of biopharmaceuticals in combating diseases.

In February 2025, Zydus Lifesciences introduced VaxiFlu-4, India's first quadrivalent influenza vaccine, marking a significant leap in vaccine technology. This novel flu protection vaccine, developed at Zydus's Vaccine Technology Centre in Ahmedabad, has been formulated according to the WHO recommended composition to combat emerging strains of the influenza virus. With clearance from the Central Drug Laboratory, VaxiFlu-4 is expected to play a crucial role in preventing flu outbreaks and addressing public health challenges. This innovation exemplifies how advancements in vaccine development are bolstering disease prevention strategies and contributing to the growth of the biopharmaceutical industry.

Global Biopharmaceutical Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biopharmaceutical market report based on molecule type, disease, drug type, drug development type, formulation, route of administration, prescription type, sales channel, and region:

• Molecule Type Outlook (Revenue, USD Million, 2021 - 2033)
• Monoclonal Antibody
• Interferon
• Insulin
• Growth and Coagulation Factor
• Erythropoietin
• Vaccine
• Hormone
• Others
• Disease Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Blood Disorder
• Metabolic Disease
• Infectious Disease
• Cardiovascular Disease
• Neurological Disease
• Immunology
• Other Applications
• Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
• Proprietary (Branded)
• Biosimilars
• Drug Development Type Outlook (Revenue, USD Million, 2021 - 2033)
• Outsource
• In-house
• Formulation Outlook (Revenue, USD Million, 2021 - 2033)
• Injectables (IV, IM, SC)
• Inhalation/Nasal Sprays
• Other Formulations
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Parenteral (IV, IM, SC)
• Inhalation/Nasal
• Other Routes
• Prescription Type Outlook (Revenue, USD Million, 2021 - 2033)
• Prescription Medicines
• Over-the-counter (OTC) Medicines
• Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Retail Pharmacies
• Non-retail
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Molecule Type
  • 1.2.2. Disease
  • 1.2.3. Drug Type
  • 1.2.4. Drug Development Type
  • 1.2.5. Formulation
  • 1.2.6. Route of Administration
  • 1.2.7. Prescription Type
  • 1.2.8. Sales Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceutical Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Pricing Analysis

Chapter 4. Biopharmaceutical Market: Molecule Type Business Analysis

• 4.1. Molecule Type Market Share, 2025 & 2033
• 4.2. Molecule Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Molecule Type, 2021 to 2033 (USD Million)
• 4.4. Monoclonal Antibody
  • 4.4.1. Monoclonal Antibody Market, 2021 - 2033 (USD Million)
• 4.5. Interferon
  • 4.5.1. Interferon Market, 2021 - 2033 (USD Million)
• 4.6. Insulin
  • 4.6.1. Insulin Market, 2021 - 2033 (USD Million)
• 4.7. Growth and Coagulation Factor
  • 4.7.1. Growth and Coagulation Factor Market, 2021 - 2033 (USD Million)
• 4.8. Erythropoietin
  • 4.8.1. Erythropoietin Market, 2021 - 2033 (USD Million)
• 4.9. Vaccine
  • 4.9.1. Vaccine Market, 2021 - 2033 (USD Million)
• 4.10. Hormone
  • 4.10.1. Hormone Market, 2021 - 2033 (USD Million)
• 4.11. Others
  • 4.11.1. Other Type Market, 2021 - 2033 (USD Million)

Chapter 5. Biopharmaceutical Market: Disease Business Analysis

• 5.1. Disease Market Share, 2025 & 2033
• 5.2. Disease Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology Market, 2021 - 2033 (USD Million)
• 5.5. Blood Disorder
  • 5.5.1. Blood Disorder Market, 2021 - 2033 (USD Million)
• 5.6. Metabolic Disease
  • 5.6.1. Metabolic Disease Market, 2021 - 2033 (USD Million)
• 5.7. Infectious Disease
  • 5.7.1. Infectious Disease Market, 2021 - 2033 (USD Million)
• 5.8. Cardiovascular Disease
  • 5.8.1. Cardiovascular Disease Market, 2021 - 2033 (USD Million)
• 5.9. Neurological Disease
  • 5.9.1. Neurological Disease Market, 2021 - 2033 (USD Million)
• 5.10. Immunology
  • 5.10.1. Immunology Market, 2021 - 2033 (USD Million)
• 5.11. Others
  • 5.11.1. Other Type Market, 2021 - 2033 (USD Million)

Chapter 6. Biopharmaceutical Market: Drug Type Business Analysis

• 6.1. Drug Type Market Share, 2025 & 2033
• 6.2. Drug Type Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
• 6.4. Proprietary (Branded)
  • 6.4.1. Proprietary (Branded) Market, 2021 - 2033 (USD Million)
  • 6.4.2. Biosimilars
    • 6.4.2.1. Biosimilars Market, 2021 - 2033 (USD Million)

Chapter 7. Biopharmaceutical Market: Drug Development Type Business Analysis

• 7.1. Drug Development Type Market Share, 2025 & 2033
• 7.2. Drug Development Type Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Drug Development Type, 2021 to 2033 (USD Million)
• 7.4. Outsource
  • 7.4.1. Outsource Market, 2021 - 2033 (USD Million)
• 7.5. In-house
  • 7.5.1. In-house Market, 2021 - 2033 (USD Million)

Chapter 8. Biopharmaceutical Market: Formulation Business Analysis

• 8.1. Formulation Market Share, 2025 & 2033
• 8.2. Formulation Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Formulation, 2021 to 2033 (USD Million)
• 8.4. Injectables (IV, IM, SC)
  • 8.4.1. Injectables (IV, IM, SC) Market, 2021 - 2033 (USD Million)
• 8.5. Inhalation/Nasal Sprays
  • 8.5.1. Inhalation/Nasal Sprays Market, 2021 - 2033 (USD Million)
• 8.6. Other Formulations
  • 8.6.1. Other Formulations Market, 2021 - 2033 (USD Million)

Chapter 9. Biopharmaceutical Market: Route of Administration Business Analysis

• 9.1. Route of Administration Market Share, 2025 & 2033
• 9.2. Route of Administration Segment Dashboard
• 9.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
• 9.4. Parenteral (IV, IM, SC)
  • 9.4.1. Parenteral (IV, IM, SC) Market, 2021 - 2033 (USD Million)
• 9.5. Inhalation/Nasal
  • 9.5.1. Inhalation/Nasal Market, 2021 - 2033 (USD Million)
• 9.6. Other Routes
  • 9.6.1. Other Routes Market, 2021 - 2033 (USD Million)

Chapter 10. Biopharmaceutical Market: Prescription Type Business Analysis

• 10.1. Prescription Type Market Share, 2025 & 2033
• 10.2. Prescription Type Segment Dashboard
• 10.3. Market Size & Forecasts and Trend Analysis, by Prescription Type, 2021 to 2033 (USD Million)
• 10.4. Prescription Medicines
  • 10.4.1. Prescription Medicines Market, 2021 - 2033 (USD Million)
• 10.5. Over-the-counter (OTC) Medicines
  • 10.5.1. Over-the-counter (OTC) Medicines Market, 2021 - 2033 (USD Million)

Chapter 11. Biopharmaceutical Market: Sales Channel Business Analysis

• 11.1. Sales Channel Market Share, 2025 & 2033
• 11.2. Sales Channel Segment Dashboard
• 11.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
• 11.4. Retail Pharmacies
  • 11.4.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
• 11.5. Non-retail
  • 11.5.1. Non-retail Market, 2021 - 2033 (USD Million)

Chapter 12. Biopharmaceutical Market: Regional Estimates & Trend Analysis

• 12.1. Regional Market Share Analysis, 2025 & 2033
• 12.2. Regional Market Dashboard
• 12.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 12.4. North America
  • 12.4.1. North America Biopharmaceutical Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
  • 12.4.2. U.S.
    • 12.4.2.1. Key Country Dynamics
    • 12.4.2.2. Target Disease Prevalence
    • 12.4.2.3. Regulatory Framework
    • 12.4.2.4. Reimbursement Framework
    • 12.4.2.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.4.3. Canada
    • 12.4.3.1. Key Country Dynamics
    • 12.4.3.2. Target Disease Prevalence
    • 12.4.3.3. Regulatory Framework
    • 12.4.3.4. Reimbursement Framework
    • 12.4.3.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.4.4. Mexico
    • 12.4.4.1. Key Country Dynamics
    • 12.4.4.2. Target Disease Prevalence
    • 12.4.4.3. Regulatory Framework
    • 12.4.4.4. Reimbursement Framework
    • 12.4.4.5. Mexico Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 12.5. Europe
  • 12.5.1. Europe Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.5.2. UK
    • 12.5.2.1. Key Country Dynamics
    • 12.5.2.2. Target Disease Prevalence
    • 12.5.2.3. Regulatory Framework
    • 12.5.2.4. Reimbursement Framework
    • 12.5.2.5. Uk Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.5.3. Germany
    • 12.5.3.1. Key Country Dynamics
    • 12.5.3.2. Target Disease Prevalence
    • 12.5.3.3. Regulatory Framework
    • 12.5.3.4. Reimbursement Framework
    • 12.5.3.5. Germany Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.5.4. France
    • 12.5.4.1. Key Country Dynamics
    • 12.5.4.2. Target Disease Prevalence
    • 12.5.4.3. Regulatory Framework
    • 12.5.4.4. Reimbursement Framework
    • 12.5.4.5. France Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.5.5. Italy
    • 12.5.5.1. Key Country Dynamics
    • 12.5.5.2. Target Disease Prevalence
    • 12.5.5.3. Regulatory Framework
    • 12.5.5.4. Reimbursement Framework
    • 12.5.5.5. Italy Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.5.6. Spain
    • 12.5.6.1. Key Country Dynamics
    • 12.5.6.2. Target Disease Prevalence
    • 12.5.6.3. Regulatory Framework
    • 12.5.6.4. Reimbursement Framework
    • 12.5.6.5. Spain Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.5.7. Denmark
    • 12.5.7.1. Key Country Dynamics
    • 12.5.7.2. Target Disease Prevalence
    • 12.5.7.3. Regulatory Framework
    • 12.5.7.4. Reimbursement Framework
    • 12.5.7.5. Denmark Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.5.8. Sweden
    • 12.5.8.1. Key Country Dynamics
    • 12.5.8.2. Target Disease Prevalence
    • 12.5.8.3. Regulatory Framework
    • 12.5.8.4. Reimbursement Framework
    • 12.5.8.5. Sweden Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.5.9. Norway
    • 12.5.9.1. Key Country Dynamics
    • 12.5.9.2. Target Disease Prevalence
    • 12.5.9.3. Regulatory Framework
    • 12.5.9.4. Reimbursement Framework
    • 12.5.9.5. Norway Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 12.6. Asia Pacific
  • 12.6.1. Asia Pacific Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.6.2. Japan
    • 12.6.2.1. Key Country Dynamics
    • 12.6.2.2. Target Disease Prevalence
    • 12.6.2.3. Regulatory Framework
    • 12.6.2.4. Reimbursement Framework
    • 12.6.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.6.3. China
    • 12.6.3.1. Key Country Dynamics
    • 12.6.3.2. Target Disease Prevalence
    • 12.6.3.3. Regulatory Framework
    • 12.6.3.4. Reimbursement Framework
    • 12.6.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.6.4. India
    • 12.6.4.1. Key Country Dynamics
    • 12.6.4.2. Target Disease Prevalence
    • 12.6.4.3. Regulatory Framework
    • 12.6.4.4. Reimbursement Framework
    • 12.6.4.5. India Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.6.5. Australia
    • 12.6.5.1. Key Country Dynamics
    • 12.6.5.2. Target Disease Prevalence
    • 12.6.5.3. Regulatory Framework
    • 12.6.5.4. Reimbursement Framework
    • 12.6.5.5. Australia Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.6.6. South Korea
    • 12.6.6.1. Key Country Dynamics
    • 12.6.6.2. Target Disease Prevalence
    • 12.6.6.3. Regulatory Framework
    • 12.6.6.4. Reimbursement Framework
    • 12.6.6.5. South Korea Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.6.7. Thailand
    • 12.6.7.1. Key Country Dynamics
    • 12.6.7.2. Target Disease Prevalence
    • 12.6.7.3. Regulatory Framework
    • 12.6.7.4. Reimbursement Framework
    • 12.6.7.5. Thailand Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 12.7. Latin America
  • 12.7.1. Latin America Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.7.2. Brazil
    • 12.7.2.1. Key Country Dynamics
    • 12.7.2.2. Target Disease Prevalence
    • 12.7.2.3. Regulatory Framework
    • 12.7.2.4. Reimbursement Framework
    • 12.7.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.7.3. Argentina
    • 12.7.3.1. Key Country Dynamics
    • 12.7.3.2. Target Disease Prevalence
    • 12.7.3.3. Regulatory Framework
    • 12.7.3.4. Reimbursement Framework
    • 12.7.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 12.8. Middle East and Africa
  • 12.8.1. Middle East and Africa Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.8.2. South Africa
    • 12.8.2.1. Key Country Dynamics
    • 12.8.2.2. Target Disease Prevalence
    • 12.8.2.3. Regulatory Framework
    • 12.8.2.4. Reimbursement Framework
    • 12.8.2.5. South Africa Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.8.3. Saudi Arabia
    • 12.8.3.1. Key Country Dynamics
    • 12.8.3.2. Target Disease Prevalence
    • 12.8.3.3. Regulatory Framework
    • 12.8.3.4. Reimbursement Framework
    • 12.8.3.5. Saudi Arabia Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.8.4. UAE
    • 12.8.4.1. Key Country Dynamics
    • 12.8.4.2. Target Disease Prevalence
    • 12.8.4.3. Regulatory Framework
    • 12.8.4.4. Reimbursement Framework
    • 12.8.4.5. UAE Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 12.8.5. Kuwait
    • 12.8.5.1. Key Country Dynamics
    • 12.8.5.2. Target Disease Prevalence
    • 12.8.5.3. Regulatory Framework
    • 12.8.5.4. Reimbursement Framework
    • 12.8.5.5. Kuwait Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 13. Competitive Landscape

• 13.1. Participant Overview
• 13.2. Company Market Position Analysis
• 13.3. Company Categorization
• 13.4. Strategy Mapping
• 13.5. Company Profiles/Listing
  • 13.5.1. F. Hoffmann-La Roche Ltd
    • 13.5.1.1. Overview
    • 13.5.1.2. Financial Performance
    • 13.5.1.3. Product Benchmarking
    • 13.5.1.4. Strategic Initiatives
  • 13.5.2. Novartis AG
    • 13.5.2.1. Overview
    • 13.5.2.2. Financial Performance
    • 13.5.2.3. Product Benchmarking
    • 13.5.2.4. Strategic Initiatives
  • 13.5.3. AbbVie Inc.
    • 13.5.3.1. Overview
    • 13.5.3.2. Financial Performance
    • 13.5.3.3. Product Benchmarking
    • 13.5.3.4. Strategic Initiatives
  • 13.5.4. Johnson & Johnson Services, Inc.
    • 13.5.4.1. Overview
    • 13.5.4.2. Financial Performance
    • 13.5.4.3. Product Benchmarking
    • 13.5.4.4. Strategic Initiatives
  • 13.5.5. Merck & Co., Inc.
    • 13.5.5.1. Overview
    • 13.5.5.2. Financial Performance
    • 13.5.5.3. Product Benchmarking
    • 13.5.5.4. Strategic Initiatives
  • 13.5.6. Pfizer Inc.
    • 13.5.6.1. Overview
    • 13.5.6.2. Financial Performance
    • 13.5.6.3. Product Benchmarking
    • 13.5.6.4. Strategic Initiatives
  • 13.5.7. Bristol-Myers Squibb Company
    • 13.5.7.1. Overview
    • 13.5.7.2. Financial Performance
    • 13.5.7.3. Product Benchmarking
    • 13.5.7.4. Strategic Initiatives
  • 13.5.8. Sanofi
    • 13.5.8.1. Overview
    • 13.5.8.2. Financial Performance
    • 13.5.8.3. Product Benchmarking
    • 13.5.8.4. Strategic Initiatives
  • 13.5.9. GSK plc.
    • 13.5.9.1. Overview
    • 13.5.9.2. Financial Performance
    • 13.5.9.3. Product Benchmarking
    • 13.5.9.4. Strategic Initiatives
  • 13.5.10. AstraZeneca
    • 13.5.10.1. Overview
    • 13.5.10.2. Financial Performance
    • 13.5.10.3. Product Benchmarking
    • 13.5.10.4. Strategic Initiatives
  • 13.5.11. Takeda Pharmaceutical Company Limited
    • 13.5.11.1. Overview
    • 13.5.11.2. Financial Performance
    • 13.5.11.3. Product Benchmarking
    • 13.5.11.4. Strategic Initiatives
  • 13.5.12. Biogen
    • 13.5.12.1. Overview
    • 13.5.12.2. Financial Performance
    • 13.5.12.3. Product Benchmarking
    • 13.5.12.4. Strategic Initiatives
  • 13.5.13. Eli Lilly and Company
    • 13.5.13.1. Overview
    • 13.5.13.2. Financial Performance
    • 13.5.13.3. Product Benchmarking
    • 13.5.13.4. Strategic Initiatives
  • 13.5.14. Novo Nordisk A/S
    • 13.5.14.1. Overview
    • 13.5.14.2. Financial Performance
    • 13.5.14.3. Product Benchmarking
    • 13.5.14.4. Strategic Initiatives
  • 13.5.15. Amgen Inc.
    • 13.5.15.1. Overview
    • 13.5.15.2. Financial Performance
    • 13.5.15.3. Product Benchmarking
    • 13.5.15.4. Strategic Initiatives